Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine (Edurant, RPV)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
|Formulation||Dosing Recommendations||Use in Pregnancy|
|Standard Adult Dose
|Moderate to high placental transfer to fetus.b
No evidence of human teratogenicity (can rule out 2-fold increase in overall birth defects).
Two-drug regimens (e.g., RPV/DTG FDC) are not recommended in pregnancy.
a Individual antiretroviral drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories—mean or median cord blood/maternal delivery plasma drug ratio:
Key to Acronyms: AUC = area under the curve; DTG = dolutegravir; FDC = fixed-dose combination; FTC = emtricitabine; PK = pharmacokinetic; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive